AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding AIM ImmunoTech Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 15 | 13 | −2 |
| Shares | 107.3K | 106.0K | −1.27K (−1.2%) |
| Value | $293.9K | $119.8K | −$174.1K (−59.2%) |
New holders (2)
Institutions that held AIM ImmunoTech Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 125 | $141 | 0.00% |
| Intesa Sanpaolo Wealth Management | 1 | $1 | 0.00% |
Sold out (4)
Institutions that held AIM ImmunoTech Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Sabby Management, LLC | 28,855 | $79.1K |
| The PNC Financial Services Group, Inc. | 50 | $137 |
| Harbour Investments, Inc. | 10 | $27 |
| Wells Fargo & Company | 4 | $11 |